CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Executives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...